BDX - Becton, Dickinson and Company

NYSE - NYSE Delayed price. Currency in USD
241.12
-0.65 (-0.27%)
At close: 04:00PM EDT
239.65 -1.47 (-0.61%)
After hours: 07:56PM EDT
Stock chart is not supported by your current browser
Previous close241.77
Open241.58
Bid237.23 x 800
Ask245.33 x 1000
Day's range240.64 - 243.32
52-week range215.90 - 269.06
Volume772,603
Avg. volume1,048,848
Market cap68.482B
Beta (5Y monthly)0.56
PE ratio (TTM)44.32
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield3.64 (1.51%)
Ex-dividend date08 Jun 2023
1y target estN/A
All
News
  • Business Wire

    BD, BIOCORP Sign Agreement to Bring Connectivity, Traceability to Self-Administered Injectable Drugs

    FRANKLIN LAKES, N.J., October 18, 2022--Regulatory News: BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Biocorp (Paris:ALCOR), a medical device and delivery systems manufacturer based in France, today announced that they have signed an agreement with the aim of using connected technology to track adherence for self-administered drug therapies, like biologics.

  • GlobeNewswire

    Eyenovia Announces Appointments of Dr. Ellen Strahlman and Dr. Ram Palanki as New and Independent Members of its Board of Directors

    NEW YORK, July 07, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP™) therapeutics, today announced that it has appointed Dr. Ellen Strahlman and Dr. Ram Palanki as new and independent members of its Board of Directors. With these appointments, the Eyenovia Board will expand to eight seats, from six currently. “I could not be more pleased to welcome Drs. Strahlman and Palanki to